4th NOAC ‘Lixiana’ landed in 4 of ‘Big 5’ hospitals
A series of news about the 4th NOAC ‘Lixiana(edoxaban)’ to land in general hospitals have continuously followed.
According to the industry concerned on the 13th, Lixiana, the new oral anti-coagulant(NOAC) jointly sold by Daiichi Sankyo and Daewoong Pharmaceutical, succeeded in landing in 4 of t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
